Salpingo-Oophorectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Salpingo-Oophorectomy is an evidence-based approach within general and specialist surgery addressing the diagnosis, treatment, and long-term management of patients requiring this form of care. Clinical practice is informed by guidelines from international specialist societies, ensuring patients receive care that is both clinically effective and aligned with individual values and quality-of-life goals.

The management of Salpingo-Oophorectomy has evolved substantially with advances in diagnostic precision, pharmacological innovation, minimally invasive techniques, and multidisciplinary care models. Modern treatment is tailored to the individual — incorporating disease severity, comorbidities, age, functional status, and patient preferences — to achieve optimal outcomes while minimising treatment burden. Specialist centres providing Salpingo-Oophorectomy offer access to experienced clinicians, advanced technology, and comprehensive multidisciplinary teams proven to improve both safety and effectiveness of care across a range of disease presentations.

International patients seeking Salpingo-Oophorectomy at accredited hospitals in India, Thailand, Turkey, and other leading medical tourism destinations benefit from world-class specialist expertise at significantly lower cost than in the USA or UK. All content on MyMedicPlus is reviewed by the Medical Review Board for clinical accuracy and adherence to current evidence-based guidelines.

Salpingo-oophorectomy addresses a wide spectrum of gynaecological conditions:

• Ovarian cancer: BSO is a core component of surgical staging and debulking for ovarian, fallopian tube, and primary peritoneal carcinoma. Alongside hysterectomy and omentectomy, it is performed in the context of comprehensive gynaecological oncological staging.
• Risk-reducing (prophylactic) surgery in BRCA1/2 carriers: Women with confirmed BRCA1 or BRCA2 pathogenic variants face lifetime risks of ovarian cancer of 44–46% (BRCA1) and 12–20% (BRCA2). Risk-reducing bilateral salpingo-oophorectomy (RRBSO), typically recommended between ages 35–45, reduces ovarian cancer risk by approximately 90% and lowers breast cancer risk in BRCA1 carriers.
• Endometriosis: Severe, symptomatic endometriosis affecting the ovaries (endometriomas) or causing recurrent disease after conservative surgery may require BSO in women who have completed their families.
• Benign adnexal masses: Large ovarian cysts, dermoid cysts (mature cystic teratomas), cystadenomas, or tubo-ovarian abscesses not amenable to cyst-sparing surgery.
• Tubo-ovarian abscess (TOA): Severe pelvic inflammatory disease causing an abscess involving the tube and ovary that fails to respond to intravenous antibiotics.
• Chronic pelvic pain: In selected cases where ovarian or tubal pathology (e.g., ovarian remnant syndrome, hydrosalpinx) is clearly identified as the source of intractable pain.
• Hormone-sensitive cancers: BSO may be performed alongside other cancer surgery in premenopausal women with oestrogen receptor-positive breast cancer to achieve surgical oophorectomy-induced ovarian suppression.

Candidacy for salpingo-oophorectomy — and the extent of surgery (unilateral vs. bilateral) — depends on multiple interacting clinical factors:

• Confirmed pathology: All elective (non-emergency) salpingo-oophorectomies require documented indication through imaging (pelvic ultrasound, MRI, or CT), serum tumour markers (CA-125, HE4), and — where appropriate — genetic testing (BRCA1/2, Lynch syndrome).
• Age and fertility intent: In premenopausal women desiring future fertility, unilateral approach with ovarian-sparing (cystectomy) is preferred when oncologically safe. Bilateral removal in premenopausal women causes immediate surgical menopause and permanent sterility.
• Menopausal status: Postmenopausal women tolerate BSO without the immediate hormonal consequences experienced by premenopausal women. For postmenopausal women undergoing hysterectomy for benign indications, the question of whether to perform concurrent BSO requires individualised shared decision-making.
• BRCA mutation carrier counselling: RRBSO candidates should undergo formal genetic counselling, discuss timing relative to their age and cancer risk profile, and understand the menopausal consequences and HRT options before surgery.
• Surgical fitness: Standard preoperative assessment including cardiovascular evaluation, lung function, and blood tests. Obese patients or those with multiple prior abdominal surgeries may require open approach planning.
• Oncological staging requirements: For suspected or confirmed ovarian malignancy, gynaecological oncology team review is mandatory before surgical planning.

Laparoscopic salpingo-oophorectomy (preferred for benign and risk-reducing indications):

Under general anaesthesia, 3–4 small abdominal incisions (5–12 mm) are made. A laparoscope (camera) provides high-definition visualisation of pelvic structures. The fallopian tube and ovary are identified; their blood supply — the utero-ovarian ligament and the infundibulopelvic (IP) ligament containing the ovarian vessels — is sequentially sealed using bipolar diathermy, advanced energy devices (LigaSure, Harmonic scalpel), or laparoscopic clips. The specimen is placed in an endobag and removed intact to avoid spillage. Pneumoperitoneum is released, and ports are closed.

Robotic-assisted laparoscopic approach:

The Da Vinci robotic system provides enhanced 3D visualisation and wristed instrument dexterity, particularly useful in complex cases such as previous extensive adhesions, high BMI, or concurrent procedures. Outcomes are equivalent to conventional laparoscopy in skilled hands; cost is higher.

Laparotomy (open surgery):

A Pfannenstiel (bikini line) or vertical midline incision provides direct access for complex oncological surgery, extensive adhesiolysis, or emergency procedures. Allows comprehensive surgical staging (peritoneal biopsies, lymph node dissection, omentectomy) in ovarian cancer surgery that may not be feasible laparoscopically.

Vaginal approach (rarely standalone):

In selected cases during vaginal hysterectomy, the tubes and ovaries can be accessed and removed vaginally, avoiding abdominal incisions entirely. Requires appropriate anatomical access and surgeon experience.

• Cancer treatment and staging: BSO is curative-intent surgery for early-stage ovarian cancer and is essential to gynaecological oncological staging, directly impacting prognosis and subsequent chemotherapy decisions.
• Dramatic cancer risk reduction in BRCA carriers: RRBSO reduces ovarian cancer risk by approximately 90% in BRCA1/2 mutation carriers and also reduces breast cancer risk by 50% in BRCA1 carriers when performed before menopause.
• Resolution of chronic pelvic disease: BSO reliably treats bilateral endometriomas, recurrent functional ovarian cysts, tubo-ovarian abscesses, and chronic pelvic inflammatory disease when conservative measures have failed.
• Minimally invasive laparoscopic approach: Compared with open surgery, laparoscopy offers smaller scars, significantly less post-operative pain, shorter hospital stay (1–2 days), faster return to work (2 weeks vs. 4–6 weeks), and fewer wound complications.
• Prevention of contralateral tube disease: Bilateral salpingectomy (tube removal) at the time of hysterectomy or sterilisation is increasingly recommended as it reduces the risk of future tubal pathology and may reduce ovarian cancer risk (supported by evidence that many high-grade serous ovarian cancers originate in the fallopian tube fimbriae).
• Relief from recurrent ovarian cysts: Patients with recurrent simple or complex ovarian cysts requiring repeated hospital admissions gain lasting relief from removal of the affected ovary.

General surgical risks:

• Bleeding: Intraoperative haemorrhage from the ovarian vascular pedicle (infundibulopelvic ligament) is the most significant intraoperative risk. Blood transfusion is rarely required for laparoscopic benign cases but is more common in oncological surgery.
• Ureteric injury: The ureter runs in close proximity to the ovarian vessels in the retroperitoneum. Inadvertent ureteric injury during IP ligament ligation is a rare but serious complication requiring urology input and repair.
• Bowel injury: Particularly relevant in the context of endometriosis or adhesions, where bowel may be adherent to pelvic structures.
• Infection: Post-operative pelvic infection or wound infection, managed with antibiotics.
• Venous thromboembolism (VTE): DVT and pulmonary embolism risk is elevated after pelvic surgery. Low-molecular-weight heparin and compression stockings are standard prophylaxis.

Long-term consequences of bilateral oophorectomy (BSO):

• Surgical menopause: BSO in premenopausal women causes immediate onset of menopausal symptoms — hot flushes, night sweats, vaginal atrophy, mood changes, and reduced libido — which can be severe due to the abruptness of oestrogen withdrawal.
• Cardiovascular risk: Oestrogen has a cardioprotective effect; BSO before natural menopause significantly increases the risk of coronary artery disease, dyslipidaemia, and hypertension. HRT mitigates this risk substantially.
• Osteoporosis: Accelerated bone mineral density loss following BSO increases fracture risk. HRT, calcium, and vitamin D supplementation are indicated.
• Cognitive effects: Some studies suggest an association between premature BSO and increased risk of cognitive decline; the relationship is modified by HRT use.
• Permanent infertility: BSO results in permanent sterility. In premenopausal women wishing future fertility, fertility-sparing surgery (USO, cystectomy) or oocyte/embryo cryopreservation prior to BSO should be discussed.

Hospital stay (1–3 days laparoscopic; 3–5 days open): Regular analgesia, anti-emetics, and early ambulation are standard. A urinary catheter is removed within 24 hours. Diet is introduced early. Pneumatic compression stockings and LMWH injections continue until fully mobile.

First 2 weeks at home: Light activity with progressive increase. No heavy lifting, strenuous exercise, sexual intercourse, or driving until surgical review. Shower wounds daily; report signs of infection (redness, discharge, fever). Oral analgesia with paracetamol and NSAIDs is usually sufficient after laparoscopic surgery.

Surgical menopause management (after BSO in premenopausal women):

• Hormone replacement therapy (HRT) should be offered promptly to all premenopausal women undergoing BSO who have no specific contraindication (e.g., current hormone-sensitive breast cancer). HRT prevents the cardiovascular, skeletal, cognitive, and quality-of-life consequences of premature surgical menopause and is recommended until the age of natural menopause (approximately 51 years).
• Local oestrogen therapy for vaginal atrophy symptoms is effective and safe even when systemic HRT is not appropriate.

Oncological follow-up (if applicable): Women undergoing BSO for ovarian cancer undergo regular surveillance with serum CA-125, clinical examination, and imaging as per oncology protocol. BRCA carriers continue breast surveillance intensification (annual MRI plus mammography) after RRBSO.

Bone health: DEXA bone density scanning is recommended 2 years after BSO in premenopausal women; earlier if bone loss risk factors are present. Calcium (1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation is recommended for all women after BSO.

The cost of salpingo-oophorectomy varies substantially based on indication (benign vs. oncological), approach (laparoscopic vs. open), and healthcare system:

• Indication and complexity: Risk-reducing BSO for BRCA carriers is a shorter, more straightforward procedure than oncological staging surgery involving concurrent hysterectomy, omentectomy, and lymph node dissection — which can add USD 10,000–30,000 in operative and pathology costs.
• Surgical approach: Robotic-assisted laparoscopy costs USD 2,000–5,000 more than conventional laparoscopy due to robotic consumables and machine costs.
• Country of treatment: In India, laparoscopic USO or BSO for benign indications costs approximately USD 1,500–4,000 at accredited private hospitals. The same procedure costs USD 10,000–30,000 in the United States. UK private clinics typically charge GBP 4,000–10,000.
• Genetic testing costs: For BRCA carriers, the genetic testing process (GBP 200–2,000 depending on country and whether NHS/insurance funded) precedes surgery and should be factored into total planning costs.
• Hormone replacement therapy: Ongoing HRT after BSO represents a recurring cost (approximately USD 500–2,000 per year depending on formulation) that extends for years or decades.
• Anaesthesia and pathology: All specimens removed at salpingo-oophorectomy must be sent for histological examination; pathology fees are additional. Frozen section analysis during oncological surgery adds further cost.

• Ovarian cystectomy: For benign ovarian cysts (dermoids, endometriomas, simple cysts), the cyst can be removed while preserving the ovarian cortex and its follicles. Preferred in premenopausal women wishing to preserve fertility and ovarian function. Carries a higher risk of cyst recurrence compared with oophorectomy.
• Medical management of endometriosis: Hormonal suppression with combined oral contraceptives, progestins, GnRH agonists (e.g., leuprolide), or the LNG-IUD can control endometriosis symptoms and reduce cyst growth without surgery, particularly in younger women. Medical management is not curative and disease typically returns after cessation.
• Bilateral salpingectomy alone (without oophorectomy): In women at average cancer risk undergoing hysterectomy or requesting sterilisation, removal of the fallopian tubes only (opportunistic salpingectomy) — with ovaries preserved — is increasingly recommended by major gynaecological societies. This strategy may reduce the future risk of ovarian cancer (since many high-grade serous carcinomas appear to originate in the tube) while avoiding surgical menopause.
• Enhanced surveillance in BRCA carriers: For women not ready for RRBSO, intensive gynaecological cancer surveillance (transvaginal ultrasound and CA-125 every 6 months) offers earlier detection but does not match the risk-reduction achieved by RRBSO; early-stage detection rates remain insufficient to prevent ovarian cancer mortality in this population.
• Chemotherapy-first approach (neoadjuvant) in ovarian cancer: For advanced ovarian cancer (stage IIIC–IV) where optimal primary debulking is not achievable, 3–4 cycles of platinum-based chemotherapy are administered first to downsize tumour before interval debulking surgery including BSO. This approach reduces surgical morbidity without compromising overall survival compared with primary debulking in appropriate patients.